Light chain multiple myeloma, clinic features, responses to therapy and survival in a long-term study. World J Surg Oncol. 2014 Jul 28;12: 234.Zhang JJ, Sun WJ, Huang ZX, et al.: Light chain multiple myeloma, clinic features, responses to therapy and survival in a long-term study. ...
The article presents a study which determines seven single-nucleotide polymorphisms (SNPs) that are related with the disease risk of amyloid light-chain (AL) amyloidosis. The symptoms of AL which arise in the organs where amyloids accumulate including the kidneys, heart, and peripheral nerves is ...
Free light chainN-glycosylation contributes to amyloidogenicity and is a biomarker present years before onset of symptoms. • Light chain amyloidosis is a progressive disease and early diagnosis is critical to avoid irreversible organ damage and patient demise. ...
Kappa light chain multiple myeloma was diagnosed by bone marrow aspiration, biopsy and immunoelectrophoresis of serum and urine. He was treated with mephalan, prednisolone and diuretics. 展开 年份: 1994 收藏 引用 批量引用 报错 分享 全部来源 求助全文 papersearch.net 相似文献...
NCCN Guidelines Version 2.2023 Systemic Light Chain Amyloidosis Overview Primary systemic light chain amyloidosis (SLCA) in contrast to multiple myeloma is typically characterized by low burden of monoclonal plasma cells in the bone marrow. The abnormal plasma cells produce light chains that get ...
Light chain amyloidosis needs to be considered in the differential diagnosis of patients with nondiabetic nephrotic range proteinuria, unexplained fatigue or heart failure with preserved ejection fraction, a progressive peripheral neuropathy associated with a monoclonal protein, or atypical multiple myeloma. ...
Light Chain Amyloidosis Background AL results from the extracellular deposition of amyloid fibrils composed of monoclonal immunoglobulin light chains, which are produced by an underlying clonal plasma cell proliferative disorder such as multiple myeloma (MM) (Central Illustration, panel A). Ten percent ...
We defined active disease as the presence of clinical signs and symptoms, laboratory abnormalities or unequivocal radiological findings attributable to IgG4-RD. Patients with active disease included those with de novo active disease (first episode of active IgG4-RD), relapsing disease (active disease...
Eight amyloidogenic LCs were selected as responsible for severe cardiac symptoms in patients; five non-amyloidogenic LCs were isolated from patients affected by multiple myeloma. Our comprehensive approach (consisting of spectroscopic techniques, limited proteolysis, and X-ray crystallography) shows that ...
Herein, we describe the case of a 53-year-old female diagnosed with systemic mastocytosis (SM) in conjunction with renal light chain amyloidosis (AL) and smoldering myeloma. Although cytokines such as IL-6 may play a role in the proliferation of plasma cells, delays in the diagnosis of SM...